Baicalein mitigates epithelial barrier impairment and microbiota dysbiosis in allergic asthmatic mice via the gut‑lung axis
Yao Lu, Xinqian Rong, Lini Wei, Jingwen Yang, Kaiqi Zhang, Yong Tan, Ning Zhao, Xiaojuan He, Cheng Lu, Li Li · 2026
Read Baicalein mitigates epithelial barrier impairment and microbiota dysbiosis in allergic asthmatic mice via the gut‑lung axis by Yao Lu, Xinqian Rong, Lini Wei, Jingwen Yang, Kaiqi Zhang, Yong Tan, Ning Zhao, Xiaojuan He, Cheng Lu, Li Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13191896.txt.
Description
Yao Lu leads a 2026 mouse study of baicalein, a plant compound from a traditional Chinese medicine herb, for allergic asthma. Asthma attacks tighten the chest and can be fatal, and current treatments do not avert the worst outcomes. How the compound acts when swallowed was unclear, so the gut-lung axis, the link between gut microbes and lung health, was examined.
In mice with induced allergic asthma, oral baicalein eased lung lining damage and raised barrier proteins. It also repaired gut lining, enriched a beneficial gut bacterium, and raised helpful fatty acids in stool. Transplanting gut microbes from treated mice confirmed the microbe shift drove much of the benefit, calming a type of immune cell in the colon.
Catalog record
| CREATOR | Yao Lu, Xinqian Rong, Lini Wei, Jingwen Yang, Kaiqi Zhang, Yong Tan, Ning Zhao, Xiaojuan He, Cheng Lu, Li Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |